Search Results

You are looking at 41 - 50 of 113 items for :

  • "consolidation therapy" x
  • Refine by Access: All x
Clear All
Full access

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology

Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Frederick R. Appelbaum, Vijaya Raj Bhatt, Dale Bixby, Steven E. Coutre, Marcos De Lima, Amir T. Fathi, Melanie Fiorella, James M. Foran, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Thomas W. LeBlanc, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Margaret R. O’Donnell, Rebecca Olin, Deniz Peker, Alexander Perl, Daniel A. Pollyea, Keith Pratz, Thomas Prebet, Farhad Ravandi, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Matthew Wieduwilt, Kristina M. Gregory, OCN, Lydia Hammond, and Ndiya Ogba

% CI, 31.5–not reached [NR]) in the midostaurin group compared with 25.6 months (95% CI, 18.6–42.9) in the placebo group ( P =.009). 32 Patients who received midostaurin with standard induction and consolidation therapy experienced significant

Full access

Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare Perspective

Ranee Mehra, Candice Yong, Brian Seal, Marjolijn van Keep, Angie Raad, and Yiduo Zhang

, durvalumab remained cost-effective, with an ICER of $79,609 per QALY. Therefore, our analysis builds on the work of Criss et al 35 to provide a more robust estimate of the costs associated with durvalumab consolidation therapy, given current clinical

Full access

Therapeutic Advances in Relapsed or Refractory Multiple Myeloma

Kenneth C. Anderson

-thalidomide-dexamethasone compared with thalidomide-dexamethasone as consolidation therapy following double autologous transplantation for multiple myeloma: results of a qualitative and quantitative analysis . Haematologica 2011 ; 96 ( s1 ): S96 . Abstract P224 . 2

Full access

Chemotherapy in the Management of Osteosarcoma and Ewing's Sarcoma

Scott M. Schuetze

the Children's Oncology Group . J Clin Oncol 2006 ; 24 : 152 – 159 . 56. Meyers PA Krailo MD Ladanyi M . High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high

Full access

Fixed-Duration Versus Until Disease Progression: How Long Should Initial Treatment of Multiple Myeloma Last?

Yvonne A. Efebera and Nina Shah

group and Dana-Farber Cancer Institute. 2 In this study, investigators randomly assigned patients with MM to receive either (1) induction therapy with 3 cycles of lenalidomide/bortezomib/dexamethasone (RVD) and then consolidation therapy with either 5

Full access

Prognostic Significance of Molecular Markers and Targeted Regimens in the Management of Acute Myeloid Leukemia

Martin Tallman

be given for secondary AML or AML with MRC. GO can be given to patients who are CD33-positive with 7+3 induction and consolidation therapy on days 1, 4, and 7 or as a single agent days 1 and 8. The 2018 NCCN Guidelines for AML state that after

Full access

Advances in Acute Myeloid Leukemia Management: Focus on Secondary Disease and Older Patients

Presented by: Daniel A. Pollyea

CPX-351 must also be able to tolerate intensive induction chemotherapy. Ongoing research is evaluating whether CPX-351 can be given on an outpatient basis as induction or consolidation therapy. When giving glasdegib, he warned of the potential for

Full access

Management of Newly Diagnosed Multiple Myeloma Based on Risk Stratification

Presented by: Natalie S. Callander

- versus 3-drug induction regimen. 4 This trend seemed to correlate with the 4-year PFS rates (87.2% vs 70.0%, respectively). In the MASTER trial, MRD assessments guided the continuation or cessation of posttransplant consolidation therapy. 5 This

Full access

Updates in the Management of Neuroblastoma

Presented by: Rochelle Bagatell

primary tumor is radiated.” More remains to be learned about the risks and benefits of metastatic site radiation. Immunotherapy and Targeted Agents for High-Risk Disease Anti-GD2 Antibody Therapy “In post-consolidation therapy, the addition of

Full access

Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology

Shaji K. Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Michaela Liedtke, Thomas Martin, James Omel, Noopur Raje, Frederic J. Reu, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar

completion of induction was 58%. 54 After transplantation and consolidation therapy the rate of VGPR or better was 70% and 87%, respectively. 54 The phase II EVOLUTION trial was designed to examine the tolerability and efficacy of combining bortezomib